Manuel Vega, CEO at AGS Therapeutics.

pp. 13-21

‍

Summary

1. Viral-Based Delivery Systems

2. Lipid Nanoparticles (LNPs) as a Delivery System

3. Extracellular Vesicles: From Mammalian Origin to Microalgae-Derived Platforms

4. Microalgae Extracellular Vesicles (MEVs): A Next-Generation Non-Viral Delivery Platform

Acknowledgments

5. References

‍

‍

‍

‍